Managing Ibrutinib-Related Hypertension in B-Cell Malignancies: Daniel Addison, MD

​Ibrutinib is an effective treatment for several B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it can cause cardiotoxicity. Under the direction of Daniel Addison, MD, a team of researchers recently found that hypertension caused or worsened by treatment with ibrutinib results in a greater than two-fold increased risk of major adverse cardiovascular events. In this interview with i3 Health, Dr. Addison discusses what...
Continue reading

Ibrutinib Increases Hypertension and Cardiovascular Risk

For patients with B-cell malignancies, the hypertension caused or worsened by treatment with ibrutinib results in a two-fold increased risk of major adverse cardiovascular events, report researchers at The Ohio State University. Ibrutinib can be highly effective against B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it also is associated with cardiotoxicity. Severe hypertension has been reported, but "the long-term inci...
Continue reading

“Getting Their Attention: Streamlining Patient Education” With Margaret Highley, MSN, RN, OCN®, and Rebecca Grimmett, RN, OCN®

Patient education regarding the purpose and side effects of medications can be important to ensuring adherence and optimizing patient outcomes. However, it can be difficult for patients to absorb this information while experiencing an episode of acute illness, especially given the anxiety that can accompany a frightening diagnosis such as cancer. Margaret Highley, MSN, RN, OCN®, and members of the surgical oncology unit at The James Cancer Hospital and Solove Research Institute at The Ohio State...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.